A Study of Orally Administered IPG7236 in Healthy Adult Participants
Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
The study is a phase 1, randomized, double-blind, placebo-controlled, single and multiple
dose escalation study to evaluate the safety, tolerability, pharmacokinetic and food effect
of orally administered IPG7236 in healthy adult participants.